Stockscreener 앱 받기
177.05
1.88%
3.27
시간 외 거래:
177.05
전일 마감가:
$173.78
열려 있는:
$175
하루 거래량:
7.12M
Relative Volume:
1.02
시가총액:
$303.70B
수익:
$56.33B
순이익/손실:
$4.28B
주가수익비율:
73.77
EPS:
2.4
순현금흐름:
$17.83B
1주 성능:
+3.13%
1개월 성능:
-15.69%
6개월 성능:
-5.76%
1년 성능:
+4.43%
1일 변동 폭
$174.40
$178.15
1주일 범위
$168.54
$178.15
52주 변동 폭
$153.58
$218.66
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
177.05 | 303.70B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
829.42 | 744.96B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
155.38 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
NVO
Novo Nordisk Adr
|
61.30 | 279.13B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.13 | 216.43B | 51.72B | 11.94B | 13.81B | 5.88 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Buy Stock in These Healthcare Leaders as Q1 Earnings Approach? ABBV, HCA - TradingView
ABBVIE Earnings Preview: Recent $ABBV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Why AbbVie Inc. (ABBV) is Among the Best Stocks That Will Always Grow - Yahoo Finance
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi - Zacks Investment Research
Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades' - Benzinga
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings - TradingView
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - The Motley Fool
Analyst Expectations For AbbVie's Future - Benzinga
AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup NowAbbVie (NYSE:ABBV) - Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity - Nasdaq
Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom - Barron's
AbbVie (ABBV) Has a New Rating from Scotiabank - The Globe and Mail
Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy - Baystreet.ca
10 Best Stocks That Will Always Grow - Insider Monkey
Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast? - TradingView
PVT-401 achieves milestone under Parvus and Abbvie inflammatory bowel disease collaboration - BioWorld MedTech
Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't? - Yahoo Finance
This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
AbbVie (ABBV) Initiated at Overweight by Cantor Fitzgerald with $210 Price Target | ABBV Stock News - GuruFocus
AbbVie price target lowered to $200 from $223 at BofA - TipRanks
Lobbying Update: $2,110,000 of ABBVIE INC. lobbying was just disclosed - Nasdaq
AbbVie (ABBV) Stock Moves -1.64%: What You Should Know - Yahoo Finance
Jim Cramer Is Bullish on AbbVie Inc. (ABBV) Ahead of Earnings - Insider Monkey
BofA Adjusts AbbVie (ABBV) Price Target Ahead of Q1 Results | ABBV Stock News - GuruFocus
Immunology Drugs Market Top Companies Study- Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer. - openPR.com
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com
Is AbbVie Stock a Buy? - MSN
Lobbying Update: $50,000 of ABBVIE INC. lobbying was just disclosed - Nasdaq
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV - TradingView
Is AbbVie Inc. (ABBV) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Shares Sold by Canada Pension Plan Investment Board - MarketBeat
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - marketscreener.com
AbbVie (ABBV): A Top Dividend Monarch with Strong Growth Prospects - GuruFocus
Applications now open for Abbvie’s cystic fibrosis scholarship program - Cystic Fibrosis News Today
AbbVie (ABBV) Gets a Buy from Guggenheim - The Globe and Mail
Fund Update: Bank Pictet & Cie (Europe) AG added 78,930 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
AbbVie Inc. (ABBV): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
10 Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
AbbVie Inc. (ABBV): One of the Best Dividend Monarchs to Invest in Now - Insider Monkey
Interleukin Inhibitors Market Is Booming Worldwide | AbbVie - openPR.com
Drug company files suit against South Dakota over new 340B law - South Dakota Public Broadcasting
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks - Yahoo Finance
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment - Yahoo Finance
Top Research Reports for AbbVie, TJX & Charles Schwab - MSN
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.32%
1.50%
자본화:
|
볼륨(24시간):